Genmab partner receives conditional EU approval for cancer drug

The EU Commission has followed the recommendation of its expert panel and has granted Janssen conditional marketing authorization of Genmab's Rybrevant (amivantamab) for the treatment of advanced non-small cell lung cancer.

Photo: Janssen/PR

Genmab's US partner Janssen has received conditional marketing authorization for amivantamab, marketed as Rybrevant, by the EU Commission, Genmab announces in a press release on Monday.

Rybrevant has been approved for patients with advanced non-small cell lung cancer after chemotherapy has failed.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs